Computerized Thermal Imaging Announces Favorable Ruling on Appeal

Name	Symbol	Market	Type
LS 1X Coinbase Tracker ETP	EU:COIB	Euronext	Exchange Traded Fund

	Price Change	% Change	Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Traded	Last Trade
	-0.6332	-9.85%	5.797	5.8484	5.8558	5.797	5.797	5.797	0	16:35:03

LS 1X Coinbase Tracker ETP (EU:COIB)
Historical Stock Chart

From Dec 2019 to Dec 2024

Click Here for more LS 1X Coinbase Tracker ETP Charts.

Computerized Thermal Imaging Announces Favorable Ruling on Appeal Ninth Circuit Upholds Lower Court Decision OGDEN, Utah, Aug. 31 /PRNewswire-FirstCall/ -- Computerized Thermal Imaging, Inc. ("CTI") (OTC:COIB) (BULLETIN BOARD: COIB) today announced that the United States Court of Appeals for the Ninth Circuit has ruled in CTI's favor in the appeal of the United States District Court decision to dismiss the plaintiffs' claims in the proceeding entitled "In re: Computerized Thermal Imaging, Inc., Securities Litigation." The Ninth Circuit decision upheld the determination of the District Court to dismiss the plaintiff's complaint because it failed to adequately plead a case. "We have always been confident that the appellate court would rule in our favor," commented Richard V. Secord, Chairman of the Board and CEO of Computerized Thermal Imaging. "We are very pleased to put this matter behind us and focus our resources on moving our BSC 2100 infrared cancer detection device into Canada and promoting our TIP system and Photonic Stimulator. We continue to pursue FDA approval for the BCS 2100 in the United States and hope to enter the U.S. market as soon as the FDA approves the BSC 2100 device. Meanwhile, the TIP system and Photonic Stimulator continue to be sold throughout the states as well as Canada and China." About CTI CTI designs, manufactures and markets thermal imaging and infrared devices and services used for clinical diagnosis, pain management and non-destructive testing of industrial products and materials. CTI has developed six significant proprietary technologies, four of which relate to its breast imaging system, BCS 2100. These include a climate-controlled examination unit to provide patient comfort and facilitate reproducible tests for the BCS 2100; an imaging protocol designed to produce consistent results for the BCS 2100; a statistical model that detects physiological irregularities for the BCS 2100, and infrared imaging and analysis hardware, including a proprietary heat-sensing camera. CTI also markets the Thermal Image Processor and Photonic Stimulator, two cleared pain management devices used for diagnostic imaging and therapeutic treatment. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are CTI's pending application before the FDA seeking pre-market approval of CTI's BCS 2100 breast imaging system, CTI's ability to raise additional capital to fund cash requirements for future operations and CTI's ability to continue as a going concern. In particular, careful consideration should be given to cautionary statements made in the various reports CTI has filed with the Securities and Exchange Commission. CTI undertakes no duty to update or revise these forward-looking statements. DATASOURCE: Computerized Thermal Imaging, Inc. CONTACT: BJ Mendenhall of Computerized Thermal Imaging, Inc., +1-801-776-4700, ext. 31

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

COIB LS 1X Coinbase Tracker ETP